PMID- 18824136
OWN - NLM
STAT- MEDLINE
DCOM- 20090427
LR  - 20091119
IS  - 1537-1891 (Print)
IS  - 1537-1891 (Linking)
VI  - 50
IP  - 1-2
DP  - 2009 Jan-Feb
TI  - TLR-4 agonistic lipopolysaccharide upregulates interleukin-8 at the 
      transcriptional and post-translational level in vascular smooth muscle cells.
PG  - 34-9
LID - 10.1016/j.vph.2008.08.006 [doi]
AB  - Despite extensive studies on cellular responses to activation of Toll-like 
      receptor-4 (TLR-4), it is not evident weather its activation affects gene 
      expression of interleukin-8 (IL-8) in vascular smooth muscle cells (VSMCs). 
      Therefore, this study has investigated whether and how TLR-4 influences IL-8 
      expression in VSMCs. Exposure of aortic smooth muscle cells to TLR-4 agonistic 
      lipopolysaccharide (LPS) not only enhanced release of IL-8 protein but also 
      induced IL-8 gene transcript via promoter activation. The LPS-induced activation 
      of IL-8 promoter was attenuated by dominant-negative MKK1, but not by 
      dominant-negative MKK3. The promoter activation was also impaired by dominant 
      negative CCAAT/enhancer binding protein (C/EBP), IkappaB, and dominant negative 
      c-Jun. In comparison with the mutation of the AP-1 binding site, the mutation of 
      NF-kappaB site and C/EBP binding site in the IL-8 promoter region more 
      significantly impaired the promoter activation. Moreover, both promoter activity 
      and release of IL-8 were inhibited by U0126 and curcumin, but not by SB202190, 
      epigallocatechin 3-gallate and resveratrol. The present study reports that 
      TLR-4-agonistic LPS upregulates IL-8 at the transcriptional and 
      post-translational level in VSMCs, and that ERK1/2, NF-kappaB, and C/EBP play 
      major roles in the upregulation of IL-8.
FAU - Hong, Taek-Jong
AU  - Hong TJ
AD  - Department of Internal Medicine, School of Medicine-Pusan National University, 
      Busan, Republic of Korea.
FAU - Ban, Ji-Eun
AU  - Ban JE
FAU - Choi, Kyung-Ha
AU  - Choi KH
FAU - Son, Yong-Hae
AU  - Son YH
FAU - Kim, Sun-Mi
AU  - Kim SM
FAU - Eo, Seong-Kug
AU  - Eo SK
FAU - Park, Hee-Ju
AU  - Park HJ
FAU - Rhim, Byung-Yong
AU  - Rhim BY
FAU - Kim, Koanhoi
AU  - Kim K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080913
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (CCAAT-Enhancer-Binding Proteins)
RN  - 0 (Interleukin-8)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (RNA, Messenger)
RN  - 0 (TLR4 protein, human)
RN  - 0 (Toll-Like Receptor 4)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Aorta/cytology/metabolism
MH  - CCAAT-Enhancer-Binding Proteins/genetics/metabolism
MH  - Cells, Cultured
MH  - Humans
MH  - Interleukin-8/genetics/*metabolism
MH  - Lipopolysaccharides/pharmacology
MH  - Muscle, Smooth, Vascular/*metabolism
MH  - NF-kappa B/genetics
MH  - Promoter Regions, Genetic
MH  - RNA Processing, Post-Transcriptional/drug effects
MH  - RNA, Messenger/metabolism
MH  - Signal Transduction/drug effects
MH  - Toll-Like Receptor 4/agonists/*metabolism
MH  - Transcription, Genetic/drug effects
MH  - Transcriptional Activation/drug effects
MH  - Up-Regulation/drug effects
MH  - p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism
EDAT- 2008/10/01 09:00
MHDA- 2009/04/28 09:00
CRDT- 2008/10/01 09:00
PHST- 2008/05/14 00:00 [received]
PHST- 2008/08/20 00:00 [revised]
PHST- 2008/08/22 00:00 [accepted]
PHST- 2008/10/01 09:00 [entrez]
PHST- 2008/10/01 09:00 [pubmed]
PHST- 2009/04/28 09:00 [medline]
AID - S1537-1891(08)00112-2 [pii]
AID - 10.1016/j.vph.2008.08.006 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2009 Jan-Feb;50(1-2):34-9. doi: 10.1016/j.vph.2008.08.006. Epub 
      2008 Sep 13.